About this trial
Cognitive impairment is one of the fastest growing diseases in the last decades, given the significant increase in senior citizen population in Mexico and the world.
Several studies have discussed the gut-microbiota-brain axis. It has been demonstrated that a balanced gut microbiota, prevents an increase in pro-inflammatory cytokines that affect specific brain areas; having an important impact at the cortical level of the hippocampus which translates to diminished cognitive function and the start of cognitive impairment symptoms.
After multiple studies on the effect of the administration of symbiotics in animal models in cognition and memory, there have been positive results, observing improvement in cognition and decrement in inflammatory cytokines at hippocampus level.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients with mild cognitive impairment
Patients who sign the informed consent
Disqualifiers
Patients who do not have mild cognitive impairment
Patients with advanced cognitive impairment such as Alzheimers disease
Patients with comorbidities that influence the cognitive functions such as diabetes mellitus, cerebral ischemia or previous brain trauma
Patients who do not sign the informed consent
Trial design
Crossover
Treatments tested in this trial
Enteroccocus Facieum and Agave Inulin
Dietary supplementA pack of symbiotic powder with 1 gram of e. facieum and 8g of agave inulin will be administered daily for 8 weeks
Placebo
Other interventionA pack of unsweetened almond powder milk will be administered daily for 8 weeks
Treatment groups
Trial outcomes
Primary outcomes
Cognitive impairment
Change in Score for Mini mental state examination
Cognitive impairment
Change in Score for Rey-Osterrieth complex figure
Cognitive impairment
Change in Score for AeRAC (Instrumento de expectativas de autoeficacia)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.